– German Chancellor discussed fostering antibiotics research and inaugurated new high-tech manufacturing facility –
Paris and Frankfurt – May 28, 2015 – German Chancellor Dr. Angela Merkel met with Sanofi Chief Executive Officer Dr. Olivier Brandicourt, Boris Rhein, Hesse’s Minister for Science and the Arts, leaders of the Fraunhofer Society and researchers from Sanofi to discuss the current status of antibiotics research and to gather ideas for encouraging and fostering additional antibiotics research initiatives.
The emerging concern about antibiotic resistance has led to calls by elected officials and global health leaders to invest in developing new antibiotic therapies. In fact, the G7 Summit, hosted by Chancellor Merkel and held June 7-8 in Germany, will address the topic of antibiotic resistance. At the beginning of 2014, Sanofi and the Fraunhofer Society established a Natural Product Center of Excellence where scientists from Sanofi and Fraunhofer work to identify novel active compounds to accelerate the discovery and development of new antibiotics.
Following the antibiotics research discussion, Chancellor Merkel and Dr. Brandicourt officially inaugurated a new, high-tech manufacturing facility that is expected to supply Sanofi’s new insulin to patients throughout the world. This is one of the most cutting-edge facilities for large volume manufacturing of sterile biologics and incorporates the most modern technology enabling Sanofi to achieve the highest sterility standards in the industry.
“Sanofi is very proud that Chancellor Merkel visited our Frankfurt site, which is Sanofi’s largest, integrated site,” said Dr. Olivier Brandicourt, Chief Executive Officer, Sanofi. “The Chancellor interacted with research leaders from Sanofi and the Fraunhofer Society to discuss ideas for fueling additional antibiotics research and inaugurated Sanofi’s new, high-tech manufacturing facility, which is Sanofi’s global production facility for its new insulin therapy for people with diabetes.”
Sanofi has invested more than €1 billion in high-technology at Frankfurt-Höchst within the past ten years. At the end of 2014, Sanofi announced further investments of €200 million and, as part of that, created 500 new jobs within the last six months focused on expanding Sanofi’s biologics manufacturing capacity. In 2015, Sanofi intends to invest another €100 million to further enhance its high technology production capabilities. Sanofi’s presence in Frankfurt includes research and development, biotechnology, production and worldwide distribution of pharmaceutical products, as well as development and production of medical devices.
About the Sanofi-Fraunhofer Center of Excellence for Research into Natural Substances
At the beginning of 2014, Sanofi and the Fraunhofer Society established a Natural Product Center of Excellence where scientists from Sanofi and Fraunhofer work in joint laboratories and conduct research into new antibiotics, especially to combat gram-negative bacteria, against which there has not been any new active substance for 50 years, but which represent an increasing threat due to growing resistance.
The Sanofi-Fraunhofer Natural Product Center of Excellence is affiliated with the LOEWE Center for Insect Biotechnology in Gießen. At present, all employees work in Sanofi labs at Höchst Industrial Park, which is also home to “the heart” of the cooperation venture: One of the world’s most extensive collections of strains, comprising more than 100,000 microorganisms. The Hessian Ministry for Science and the Arts will fund the joint research into antibiotics over six years under its promotion program LOEWE.
About Sanofi-Aventis Deutschland GmbH
Sanofi-Aventis Germany GmbH is a subsidiary of Sanofi Group, a leading, integrated healthcare group, which is aligned to meeting the needs of patients by researching, developing and marketing therapeutic solutions.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare including diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Laurence Bollack (Paris)
Tel. : +33 (0)1 53 77 46 46
Dr. Birgitt Sickenberger (Frankfurt)
Tel.: + (49) 69 305 – 30167
Tel. : +33 (0)1 53 77 45 45